author-photo

Isabelle Genvresse

Bayer

13

Papers

57

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
A Phase 1 Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel using a novel Randomized Continual Reassessment Method for Dose Escalation.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL)

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
1006OCopanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Effects of rifampin on the pharmacokinetics of copanlisib, a novel pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in cancer patients.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
67PPI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

2017 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity

2017 Blood
Show All
- Source
- Cite
- Save
Citations (4)
INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)